BioSpace News Archive

Nimbus Therapeutics announced the promotion of Chief Medical Officer, Annie C. Chen, M.D., MPH, to President of the company’s Tyk2 subsidiary, Nimbus Lakshmi, Inc.

Technavio has announced its latest market research report titled global autotransfusion devices market 2020-2024.

Vireo Health Becomes First Cannabis Company to Join Growing Coalition of Nearly 900 Organizations Committed to Promoting Workplace Diversity

Bio-Techne Corporation (NASDAQ:TECH) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Exosome Diagnostics (ExosomeDx) laboratory based on results of a recent on-site inspection as part of the CAP’s Accreditation Program.

Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, and Ro, a leading U.S. telehealth provider, announced today they will partner to offer high-quality remote care dedicated to weight management and prescription fulfillment of Plenity

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with either shoulder osteoarthritis (OA) or adhesive capsulitis (AC), also known as frozen shoulder.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), today announced positive topline results from the Company’s global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heterozygous CF subjects 18 years of age and older

Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey Nau, PhD, MMS, President and CEO, is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 7:30 a.m. Pacific Time at the Westin St. Francis in San Francisco, CA.

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has granted orphan drug designation to Dicerna’s DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA)

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has initiated promotion of Aemcolo® (rifamycin) in the U.S. for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia Coli (E. coli) in adults